Cytokine Dynamics in Alzheimer’s Disease Pathogenesis

Alzheimer’s disease (AD) is characterised not only by amyloid plaques and tau tangles but also by a complex network of immune signalling molecules that drive neuronal dysfunction and degeneration. Cytokines and chemokines, secreted by activated microglia, astrocytes and infiltrating peripheral cells, exert both protective and deleterious effects on synaptic integrity, protein clearance and vascular health. Early in the disease, a shift toward pro-inflammatory mediators such as tumour necrosis factor-α, interleukin-1β and C-C motif chemokines disrupts autophagy and promotes accumulation of misfolded proteins. Concurrently, anti-inflammatory cytokines fail to counterbalance this response, leading to chronic neuroinflammation, blood-brain barrier breakdown and altered neuronal metabolism. Peripheral immune cells respond to chemokine gradients, further amplifying central inflammation via receptor-mediated signalling. Together, these dynamics establish self-sustaining loops of cytokine production, glial priming and neuronal injury, underpinning cognitive decline and clinical progression in AD.

Research from Nature Portfolio

Recent murine studies have identified the chemokine receptor CCR3 as a central regulator of age-related neuroinflammation. Inhibition of CCR3 in peripheral T cells reduced their infiltration across the blood-brain barrier, attenuated glial activation and preserved cognitive function in mouse models of Alzheimer’s pathology. This highlights a therapeutically tractable axis linking systemic immunity to central disease processes. In parallel, longitudinal human cohort analyses have demonstrated that elevated plasma levels of monocyte chemoattractant protein-1 (MCP-1/CCL2) correlate with greater disease severity and accelerated cognitive decline. Genetic variation in the MCP-1 receptor CCR2 further modulates these associations, suggesting that MCP-1/CCR2 signalling may serve as both a biomarker of progression and a target for intervention.

Cytokine Dynamics in Alzheimer’s Disease Pathogenesis publication trend

The graph below shows the total number of articles in cytokine dynamics in alzheimer’s disease pathogenesis across all publications each year (not limited to Nature Index journals).

Technical terms

Cytokine: small secreted protein that regulates immune and inflammatory responses.

Chemokine: subtype of cytokine directing the migration of immune cells.

Microglia: central nervous system immune cells that mediate neuroinflammatory reactions.

Blood-brain barrier: selective endothelial barrier controlling the exchange between blood and brain.

CCR3: a chemokine receptor involved in peripheral T-cell migration across the blood-brain barrier.

MCP-1 (CCL2): monocyte chemoattractant protein-1, a chemokine attracting monocytes and microglia.

CCR2: chemokine receptor for MCP-1 that modulates monocyte recruitment and signalling.

References

1. CCR3 plays a role in murine age-related cognitive changes and T-cell infiltration into the brain. Communications Biology (2023).
2. Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer’s Disease and Mild Cognitive Impairment: A Two-year Follow-up Study. Scientific Reports (2018).
3. Blood and CSF chemokines in Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis. Alzheimer's Research & Therapy (2023).
4. Neuroinflammation, cerebrovascular dysfunction and diurnal cortisol biomarkers in a memory clinic cohort: Findings from the Co-STAR study. Translational Psychiatry (2024).
5. Genetic Polymorphisms in Oxidative Stress and Inflammatory Pathways as Potential Biomarkers in Alzheimer’s Disease and Dementia. Antioxidants (2023).